(a) Comparison of general data among 3 groups
| Variables | Improved RDW group (n = 80) | Stable RDW group (n = 80) | Worsened RDW group (n = 68) | F/χ2 | p value |
|---|---|---|---|---|---|
| Gender/male | 46 (57.50) | 54 (67.50) | 40 (58.80) | 1.960 | 0.375 |
| Age (years) | 61.00 (9.00) | 60.50 (16.00) | 63.00 (9.00) | 3.33 | 0.180 |
| Smoking | 32 (40.00) | 40 (50.00) | 26 (38.20) | 2.523 | 0.283 |
| Drinking | 28 (35.00) | 36 (45.00) | 18 (26.5) | 5.530 | 0.043 |
| Hypertension | 46 (57.50) | 50 (62.50) | 52 (76.50) | 6.123 | 0.047 |
| Diabetes | 18 (22.50) | 24 (30.00) | 14 (20.60) | 2.040 | 0.361 |
| Duration of DAPT | 70 (87.50) | 74 (92.50) | 64 (94.10) | 2.261 | 0.323 |
| ACEI | 40 (50.00) | 32 (40.00) | 34 (50.00) | 2.087 | 0.352 |
| ARB | 8 (10.30) | 16 (20.00) | 14 (20.60) | 3.671 | 0.160 |
| Β-blocker | 54 (67.50) | 50 (62.50) | 46 (67.60) | 0.593 | 0.743 |
| CCB | 26 (32.50) | 24 (30.00) | 20 (29.40) | 0.193 | 0.908 |
| Statin | 74 (92.50) | 75 (93.75) | 64 (94.12) | 0.993 | 0.841 |
| LVEF (%) | 55.71 ± 7.62 | 54.93 ± 5.33 (19.50) | 56.36 ± 8.69 | 1.137 | 0.566 |
| SBP (mmHg) | 137.50 ± 12.26 | 138.21 ± 12.19 (10.00) | 135.93 ± 11.82 | 1.316 | 0.518 |
| DBP (mmHg) | 79.89 ± 13.53 | 81.00 ± 15.11 (19.50) | 78.93 ± 12.89 | 4.498 | 0.105 |
| Grace scores | 97.40 ± 14.66 | 98.51 ± 16.76 | 97.91 ± 15.97 | 4.164 | 0.119 |
ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blockers; CCB: calcium channel blocker; DAPT: dual antiplatelet drug therapy; DBP: diastolic blood pressure; LVEF: left ventricular ejection fraction; RDW: red cell distribution width; SBP: systolic blood pressure.